Literature DB >> 10580027

Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers.

P L Porter1, A Y El-Bastawissi, M T Mandelson, M G Lin, N Khalid, E A Watney, L Cousens, D White, S Taplin, E White.   

Abstract

BACKGROUND: Although mammographic screening is useful for detecting early breast cancer, some tumors are detected in the interval between screening examinations. This study attempted to characterize fully the tumors detected in the two different manners.
METHODS: Our study utilized a case-control design and involved a cohort of women undergoing mammographic screening within the defined population of a health maintenance organization (the Group Health Cooperative of Puget Sound). Women were classified as having "interval" or "interval-detected" cancers (n = 150) if their diagnosis was made within 24 months after a negative-screening mammogram or one that indicated a benign condition. Cancers were classified as "screen detected" (n = 279) if the diagnosis occurred after a positive assessment by screening mammography. Tumors from women in each group were evaluated for clinical presentation, histology, proliferative characteristics, and expression of hormone receptors, p53 tumor suppressor protein, and c-erbB-2 protein.
RESULTS: Interval-detected cancers occurred more in younger women and were of larger tumor size than screen-detected cancers. In unconditional logistic regression models adjusted for age and tumor size, tumors with lobular (odds ratio [OR] = 1.9; 95% confidence interval [CI] = 0.9-4.2) or mucinous (OR = 5.5; 95% CI = 1.5-19.4) histology, high proliferation (by either mitotic count [OR = 2.9; 95% CI = 1.5-5.7] or Ki-67 antigen expression [OR = 2.3; 95% CI = 1.3-4.1]), high histologic grade (OR = 2.1; 95% CI = 1.2-4.0), high nuclear grade (OR = 2.0; 95% CI = 1.0-3.7), or negative estrogen receptor status (OR = 1.8; 95% CI = 1.0-3.1) were more likely to surface in the interval between screening examinations. Tumors with tubular histology (OR = 0.2; 95% CI = 0.0-0.8) or with a high percentage of in situ components (50%) (OR = 0.5; 95% CI = 0.2-1.2) were associated with an increased likelihood of screen detection.
CONCLUSIONS: Our data from a large group of women in a defined population indicate that screening mammography may miss tumors of lobular or mucinous histology and some rapidly proliferating, high-grade tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580027     DOI: 10.1093/jnci/91.23.2020

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  84 in total

1.  Single nucleotide polymorphism array analysis of flow-sorted epithelial cells from frozen versus fixed tissues for whole genome analysis of allelic loss in breast cancer.

Authors:  Elizabeth L Schubert; Li Hsu; Laura A Cousens; Jeri Glogovac; Steve Self; Brian J Reid; Peter S Rabinovitch; Peggy L Porter
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

2.  Climacteric Complaints after Breast Cancer - Is HRT an Option?

Authors:  Christian F Singer
Journal:  Breast Care (Basel)       Date:  2008-06-20       Impact factor: 2.860

3.  Breast cancer screening, diagnostic accuracy and health care policies.

Authors:  Jean-Luc Urbain
Journal:  CMAJ       Date:  2005-01-18       Impact factor: 8.262

4.  Acculturation and its relationship to smoking and breast self-examination frequency in African American women.

Authors:  Josephine S Guevarra; Naa Oyo A Kwate; Tricia S Tang; Heiddis B Valdimarsdottir; Harold P Freeman; Dana H Bovbjerg
Journal:  J Behav Med       Date:  2005-04

5.  US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.

Authors:  Nadia Howlader; Sean F Altekruse; Christopher I Li; Vivien W Chen; Christina A Clarke; Lynn A G Ries; Kathleen A Cronin
Journal:  J Natl Cancer Inst       Date:  2014-04-28       Impact factor: 13.506

6.  Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.

Authors:  Christopher I Li; Justin E Mirus; Yuzheng Zhang; Arturo B Ramirez; Jon J Ladd; Ross L Prentice; Martin W McIntosh; Samir M Hanash; Paul D Lampe
Journal:  Breast Cancer Res Treat       Date:  2012-08-19       Impact factor: 4.872

Review 7.  Screening for breast cancer.

Authors:  Joann G Elmore; Katrina Armstrong; Constance D Lehman; Suzanne W Fletcher
Journal:  JAMA       Date:  2005-03-09       Impact factor: 56.272

8.  Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population.

Authors:  Aruna Kamineni; Melissa L Anderson; Emily White; Stephen H Taplin; Peggy Porter; Rachel Ballard-Barbash; Kathleen Malone; Diana S M Buist
Journal:  Cancer Causes Control       Date:  2012-12-07       Impact factor: 2.506

9.  Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study.

Authors:  Emily Banks; Gillian Reeves; Valerie Beral; Diana Bull; Barbara Crossley; Moya Simmonds; Elizabeth Hilton; Stephen Bailey; Nigel Barrett; Peter Briers; Ruth English; Alan Jackson; Elizabeth Kutt; Janet Lavelle; Linda Rockall; Matthew G Wallis; Mary Wilson; Julietta Patnick
Journal:  BMJ       Date:  2004-08-28

10.  Method of detection of breast cancer in low-income women.

Authors:  Amardeep Thind; Allison Diamant; Lalima Hoq; Rose Maly
Journal:  J Womens Health (Larchmt)       Date:  2009-11       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.